Multi-observer concordance and accuracy of the British Thoracic Society scale and other visual assessment qualitative criteria for solid pulmonary nodule assessment using FDG PET-CT by Fatania, K et al.
This is a repository copy of Multi-observer concordance and accuracy of the British 
Thoracic Society scale and other visual assessment qualitative criteria for solid pulmonary 
nodule assessment using FDG PET-CT.




Fatania, K, Brown, PJ, Xie, C et al. (6 more authors) (2020) Multi-observer concordance 
and accuracy of the British Thoracic Society scale and other visual assessment qualitative 
criteria for solid pulmonary nodule assessment using FDG PET-CT. Clinical Radiology. 
ISSN 0009-9260 
https://doi.org/10.1016/j.crad.2020.06.028
© 2020 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved. 





This article is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs 
(CC BY-NC-ND) licence. This licence only allows you to download this work and share it with others as long 
as you credit the authors, but you can’t change the article in any way or use it commercially. More 
information and the full terms of the licence here: https://creativecommons.org/licenses/ 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
Multi-observer concordance and accuracy of the BTS scale and other visual assessment 
qualitative criteria for solid pulmonary nodule (SPN) assessment with FDG PET-CT 
Authors 
Fatania K1, Brown PJ1, Xie C2, McDermott G3, Callister MEJ4, Graham R5, Subesinghe M6,7, 
Gleeson FV2, Scarsbrook AF1,8 
Affiliations 
1Department of Radiology, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, UK 
2Department of Radiology, Oxford University Hospitals Foundation Trust, Oxford, UK 
3Department of Medical Physics, Leeds Teaching Hospitals NHS Trust, Leeds, UK 
4Department of Respiratory Medicine, Leeds Teaching Hospitals NHS Trust, Leeds, UK 
5Department of Radiology, Royal United Hospitals Bath NHS Foundation Trust, Bath, UK 
6King s College London  Gu s and St  Thomas  PET Centre  St Thomas  Hospital  London  
UK 
7Department of Cancer Imaging, School of Biomedical Engineering and Imaging Sciences, 
King s College London  London  UK 
8Leeds Institute of Research at St James  Universit  of Leeds  UK 
Corresponding Author 





Declaration of Interest Statement 
Fergus Gleeson is a share holder in Optellum 
Funding 
This research did not receive any specific grant from funding agencies in the public, 
commercial, or not-for-profit sectors. However, the salaries of PB and KF, and part of the 
salary for AS were covered by a grant from Leeds Cares. 
Author Contributions 
1 guarantor of integrity of the entire study – Andrew Scarsbrook 
2 study concepts and design – Andrew Scarsbrook 
3 literature research – Kavi Fatania, Manil Subesinghe 
4 clinical studies – Kavi Fatania, Peter Brown, Cheng Xie, Garry McDermott, Matthew 
Callister, Richard Graham, Fergus Gleeson, Andrew Scarsbrook 
5 experimental studies / data analysis – Kavi Fatania 
6 statistical analysis – Kavi Fatania 
7 manuscript preparation – Kavi Fatania 
8 manuscript editing – Kavi, Fatania, Peter Brown, Manil Subesinghe, Andrew Scarsbrook
A ho  Con ib ion
Abstract 
Purpose 
To compare the inter-observer reliability and diagnostic accuracy of the BTS scale and other 
visual assessment criteria in the context of FDG PET-CT evaluation of solid pulmonary nodules 
(SPNs). 
Method 
50 patients who underwent FDG PET-CT for assessment of a SPN were identified. 7 reporters 
with varied experience at 4 centres graded FDG uptake visually using the British Thoracic 
Society (BTS) 4-point scale. 5 reporters also scored SPNs according to 3- and 5-point visual 
assessment scales and using semi-quantitative assessment (maximum standardised uptake 
value - SUVmax). Inter-observer reliability was assessed with the intra-class correlation 
coefficien  ICC  and eigh ed Cohen s kappa (𝜅). Diagnostic performance was evaluated by 
receiver operator characteristic (ROC) analysis. 
Results 
Good inter-observer reliability was demonstrated with the BTS scale (ICC = 0.78, 95% CI 0.69-
0.85) and 5-point scale (ICC = 0.78, 95 CI 0.68-0.86), whilst the 3-point scale demonstrated 
moderate reliability (ICC = 0.70, 95% CI 0.59-0.80). Almost perfect agreement was achieved 
between 2 consultants (𝜅 = 0.85), and substantial agreement between 2 other consultants (𝜅 
= 0.78) using the BTS scale. ROC curves for the BTS and 5-point scales demonstrated 
equivalent accuracy (BTS AUC = 0.768; 5-point AUC = 0.768). SUVmax was no more accurate 
compared to the BTS scale (SUVmax AUC = 0.794; BTS AUC = 0.768, p = 0.43). 
Ab ac
Conclusions 
The BTS scale can be applied reliably by reporters with varied levels of PET-CT reporting 
experience, across different centres and has a diagnostic performance that is not surpassed 
by alternative scales. 
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2 
Introduction 24 
Risk stratification of patients found to have a solid pulmonary nodule (SPN) on imaging helps 25 
guide optimal management, allowing improved identification and treatment for malignant 26 
lesions whilst reducing intervention and harm in patients with benign disease. 2-deoxy-2-27 
[18F]fluoro-D-glucose (FDG) positron emission tomography-computed tomography (PET-CT) is 28 
widely used to non-invasively evaluate SPNs1,2 and can improve the accuracy of risk 29 
prediction models when combined with clinical risk factors3. 30 
31 
In UK practice, the investigation and management of patients with pulmonary nodules is 32 
based upon the 2015 British Thoracic Society (BTS) guidelines, which recommend a clinico-33 
radiological approach to risk stratification4,5. Following the detection of a SPN on initial CT, 34 
the estimated likelihood of malignancy is determined using the Brock model6, stratifying 35 
patients into either < or > 10% risk of malignancy based upon CT findings (nodule size, count, 36 
type, location, spiculation, emphysema) and patient risk factors (age, gender, history of lung 37 
cancer). Those with >10% risk of malignancy undergo further assessment with FDG PET-CT, 38 
and risk stratification using the Herder model. The combination of SPN FDG uptake 39 
assessment and other clinico-radiological risk factors in the Herder model has been shown to 40 
improve diagnostic accuracy 3, which has been validated and confirmed in a UK population7. 41 
42 
The Herder model requires SPN FDG uptake to be classified according to a 4-point ordinal 43 
scale (none, faint, moderate and intense); the BTS guideline development group adapted the 44 
Herder model 4-point visual assessment scale by providing definitions for the categories of 45 
FDG uptake with reference to background uptake in the lungs and mediastinal blood pool 46 
(MBP)4,8,9. The BTS scale is the recommended method for assessment of FDG uptake in SPNs 47 
3 
in UK practice10,11, and has been shown recently to have very good inter-observer 48 
agreement within single UK institutions 12,13. However, in order to demonstrate that this 49 
high ag ee e  i hi  i i i  i  d e  c  ai i g e h d   i ila  e i g 50 
techniques, it would be reassuring to reproduce these results across different institutions. 51 
Given that the BTS scale is widely used across centres in the UK, it is necessary to establish 52 
whether inter-observer agreement is of a sufficiently high standard across different UK 53 
institutions and between reporters with varying levels of PET-CT reporting experience, to 54 
confirm that the BTS scale is likely to be consistently applied nationwide. In addition, other 55 
visual assessment scales have been proposed to assess FDG uptake in SPN8, which have not 56 
been compared to the BTS scale, between reporters working across different UK institutions. 57 
58 
To the best of our knowledge, the BTS scale has not been assessed with regard to its inter-59 
observer agreement between reporters working in different UK institutions, nor compared 60 
against other visual assessment scales. The aims of this study were to evaluate the inter-61 
observer agreement across multiple reporters at 4 different UK centres and assess the relative 62 
diagnostic accuracy of 3 visual assessment scales of FDG uptake: i) BTS scale, ii) a 5-point scale 63 





Patient selection 68 
The reporting data set comprised initial pre-treatment FDG PET-CT scans performed in 50 69 
patients with SPNs, who were randomly selected from an institutional database of patients 70 
at a single tertiary referral centre and who were subsequently assessed in nodule follow-up 71 
clinics between 2008 and 2013. Patients were included in this study if they had a SPN, and 72 
the diameter of their dominant SPN was between 8 and 30mm; 8mm is the minimum 73 
threshold size for resolving FDG uptake with a SPN4, and this range of nodule size reflects the 74 
standard practice of nodule assessment for UK departments7. Patients with part-solid or 75 
ground glass nodules were not included. Patients with a history of extra-pulmonary sites of 76 
malignancy and a new SPN were included as the Herder model accounts for a history of extra-77 
pulmonary malignancy in the assessment of a SPN, and this also reflects the reality of SPN 78 
evaluation practice. 79 
80 
Final diagnosis was considered benign when histopathology demonstrated a benign 81 
condition, the SPN remained stable over 2 years of radiological follow-up, or the SPN 82 
spontaneously decreased or resolved without treatment. A SPN was considered malignant 83 
when histopathology confirmed primary lung cancer, there was serial interval growth of the 84 
SPN on imaging and treatment for malignancy was instigated, or the patient was known to 85 
have a histologically confirmed extra-pulmonary malignancy and new lung nodules were 86 
consistent with metastases radiologically. If patients had multiple nodules, only the largest 87 
SPN was considered for the study. 88 
89 
5 
Prospective consent was obtained from all patients at the time of imaging for use of their 90 
anonymised FDG PET-CT imaging data in research and service development projects. All 91 
patients were prospectively entered into a departmental database used for retrospective 92 
identification and audit. Formal ethics committee approval was waived for this study which 93 
was considered by the institutional review board to represent evaluation of a routine clinical 94 
service. 95 
96 
Imaging acquisition and reconstruction 97 
A standard protocol was used for FDG PET-CT examinations with half-body acquisition from 98 
the skull base to upper thighs. Scans prior to June 2010 were performed on a 16-slice 99 
Discovery STE PET-CT scanner (GE Healthcare, Chicago, IL, USA) and from June 2010 to 100 
December 2013 on a 64-slice Philips Gemini TF64 scanner (Philips Healthcare, Best, 101 
Netherlands). The CT component was acquired with the following settings: 140kV; 80mAs; 102 
tube rotation time 0.5 seconds per rotation; 3.75mm section thickness. Patients were asked 103 
to maintain normal shallow respiration during the CT acquisition. No iodinated contrast 104 
material was administered. Serum blood glucose was routinely checked and if blood glucose 105 
was > 10 mmol/L scanning was not performed. Patients fasted for 6 hours prior to intravenous 106 
FDG injection (dose varied according to patient body weight). All scans used iterative 107 
reconstruction (details are outlined in Table 1), CT for attenuation correction, applied scatter 108 
and randoms correction. Each scanner used consistent reconstruction settings, matrix and 109 





Image Analysis 114 
PET-CT images for each patient were anonymised and distributed to each participating centre. 115 
Each reporter scored the FDG uptake within the dominant SPN independently, using the 3 116 
visual assessment scales, blinded to all clinical information about the patient including 117 
eventual diagnosis. SPNs were scored using the scales outlined in Table 2. Each nodule was 118 
scored by visually comparing the uptake of FDG within the nodule to background tissues, 119 
including the lung parenchyma, the mediastinal blood pool (lumen of the aortic arch) and the 120 
liver, and its score assigned according to the definitions provided in Table 2. Examples of 121 
pulmonary nodules from each of the categories using the 5-point scale are illustrated in 122 
Figure 1. Mediastinal blood pool FDG uptake was determined by visually assessing uptake 123 
within the aortic arch lumen, taking care to ignore uptake in the vessel wall. Liver FDG uptake 124 
was determined by assessing the uptake within right lobe hepatic parenchyma, ignoring 125 
uptake clearly within a focal lesion (e.g. cyst), or within the vasculature. 126 
127 
Reporters received no additional training in the use of these visual assessment scales; the BTS 128 
scale is commonly used assessment scale in the reporting of PET-CT at each of the 4 129 
participating centres. Reporters varied in their prior PET-CT interpretation experience: 3 130 
ice  reporters i h le  ha   h  e e ie ce   c l a  adi l gi  who is a 131 
clea  edici e e e  i h de   ea  e e ie ce  a d  c l a  adi l gi  h  132 
a e clea  edici e e e  each i h e   ea  e e ie ce  All 7 reporters assessed 133 
SPNs using the BTS scale. Due to logistical constraints, 5 out of initial 7 reporters, including 3 134 
consultants and 2 novice reporters, also scored SPNs using the 3 and 5-point visual 135 
assessment scales and by semi-quantitative assessment (SUVmax) at the same time as using 136 
the BTS scale. Semi-quantitative assessment consisted of drawing a region of interest (ROI) 137 
7 
around the SPN, and the maximum FDG uptake within this was calculated by the reporting 138 
software. 139 
140 
Statistical Analysis 141 
Agreement between observers was measured using two-way random effects intraclass 142 
correlation coefficient (ICC) for multi-rater agreement a d eigh ed C he  ka a 𝜅) for 143 
pair-wise agreement. ICC values below 0.5 indicate poor reliability, between 0.5 and 0.75 144 
indicate moderate reliability, between 0.75 and 0.9 indicate good reliability and above 0.9 145 
indicate excellent reliability14. Kappa values between 0.81 and 1 indicate almost perfect 146 
agreement, between 0.61 and 0.8 substantial agreement, and between 0.41 and 0.6 147 
moderate agreement15. Diagnostic performance (i.e. discrimination of malignant from 148 
benign SPNs) of each visual assessment scale and semi-quantitative assessment with SUVmax, 149 
was assessed using the total area under the curve (AUC) from receiver operator characteristic 150 
(ROC) curves separately averaged across all reporters and across expert reporters only. 151 
Derivation of the averaged AUC was based on multi-rater multi-case (MRMC) statistical 152 
analysis developed by Gallas et al. and described elsewhere16, and AUCs for each assessment 153 
scale were compared using a t-test as outlined by Hillis et al.17  this analysis was performed 154 
with the freely available software package (iMRMC: Multi-Reader, Multi-Case Analysis 155 
Methods; Version 1.2.0). Other statistical analyses were performed using SPSS (Version25; 156 





Demographic data and nodule characteristics 161 
50 patients were included in the study. Demographic information and SPN characteristics are 162 
provided in Table 3.  The median age was 67 years (IQR 62-75 years) and 21 of the 50 patients 163 
were male (42%). 40 patients (80%) were current or former smokers and there were 37 164 
patients (74%) with an eventual diagnosis of malignancy  30 patients with primary lung 165 
malignancy and 7 with pulmonary metastases from an extra-pulmonary primary malignancy 166 
 the majority of patients with pulmonary metastases had metastatic colorectal carcinoma (5 167 
patients, 10%). Median SPN diameter was 16mm (IQR 11.5-23.5mm). The mean SUVmax for 168 
benign SPNs was 2.5 (range 0.6-5.8), and for malignant SPNs 5.4 (range 1.2-12.4). 169 
170 
Interobserver agreement 171 
Table 4 summarises the results of inter-observer agreement analysis. Inter-observer 172 
reliability for the BTS scale, for all 7 reporters including consultants and novices (ICC = 0.78, 173 
95% CI 0.69-0.85), and between all 4 consultants (ICC = 0.77, 95% CI 0.67-0.85) was good. 5 174 
out of 7 reporters, including 3 consultants and 2 novice reporters, also scored SPNs using the 175 
3 and 5-point visual assessment scales and by semi-quantitative assessment (SUVmax). For the 176 
5-point scale, agreement between all 5 reporters (ICC = 0.78, 95 CI 0.68-0.86), and between177 
3 consultants (ICC = 0.75, 95% CI 0.63-0.84) was good. For the 3-point scale, agreement 178 
between all 5 reporters (ICC = 0.70, 95% CI 0.59-0.80), and between 3 consultants (ICC = 0.64, 179 
95% CI 0.49 0.76) was moderate. 180 
181 
Pair-wise analysis of agreement was performed for the BTS scale. Weighted 𝜅 demonstrated 182 
almost perfect agreement between 2 consultants, one with under (expert 1), and the other 183 
9 
with over 10 ea  e e ie ce (expert 2) (𝜅 = 0.85), and substantial agreement between 2 184 
consultants both i h e   ea  e e ie ce (expert 3 vs expert 4) (𝜅 = 0.78) all working 185 
across different centres. Comparison of agreement between one consultant with over 10 186 
ea  e e ie ce i h e e  f ed ced e e ie ce al  de a ed b a ial 187 
agreement (expert 4 vs novice 1 𝜅 = 0.71, expert 4 vs expert 2 𝜅 =0.75). 188 
189 
Diagnostic accuracy 190 
Table 5 summarises the AUCs from ROC analysis for visual assessment scales and semi-191 
quantitative assessment (SUVmax), and Figure 2 illustrates ROC curves for each assessment 192 
method. ROCs for the BTS and 5-point scales demonstrated equivalent overall accuracy (BTS 193 
= 0.768; 5-point  AUC = 0.768). The BTS scale demonstrated improved accuracy compared to 194 
the 3-point scale, although did not reach statistical significance (BTS AUC = 0.768; 3-point AUC 195 
= 0.715, p = 0.08 (Hillis, t-test)). SUVmax did not demonstrate statistically significant higher 196 





Our study demonstrates good interobserver agreement of BTS scale, which is not improved 201 
by using a 3- or 5-point scale. The BTS scale has similar diagnostic performance across a range 202 
of reporters and sites of practice compared with other assessment methods including semi-203 
quantitative FDG uptake measurement. The 2015 BTS guidelines for SPN evaluation advocate 204 
the use of an ordinal visual assessment scale to assess FDG uptake in SPNs on PET-CT, with 205 
the 4-point BTS scale the standard assessment scale in UK reporting practice 4,5. Murphy et 206 
al. demonstrated that the BTS scale has good inter-observer agreement within a single UK 207 
institution, using 2 different PET-CT reconstruction techniques 12 and our study further 208 
corroborates this by demonstrating good inter-observer agreement when using the BTS scale 209 
across multiple reporters from different institutions. Although the BTS scale has been 210 
advocated in national guidance, drawn together by collaborators across many institutions, 211 
this study confirms that multi-centre application of the BTS scale is reliable and extends the 212 
results of single-centre studies sharing similar conclusions 12,13. Furthermore, the study 213 
confirms that a 4-point BTS scale is not improved, with respect to its inter-observer 214 
agreement, by using a 3- or 5-point visual assessment scale.  In addition, reporters of varying 215 
levels of experience showed good agreement in our study, and these results suggest that SPN 216 
risk stratification using the Herder model is likely being consistently applied across different 217 
UK centres. 218 
219 
Our study used visual assessment of FDG uptake within the SPN and reference background 220 
tissues to classify SPNs according to the different assessment scales (Table 2). In the 221 
assessment of FDG PET-CT for response assessment in Hodgki  a d diff e la ge B cell 222 
lymphoma, the 5-point scale, i.e. Deauville criteria, has demonstrated high inter-observer 223 
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agreement18 20, utilising both visual assessment of FDG uptake with comparison to 224 
reference background tissues, and semi-quantitative assessment in order to confirm the 225 
results of visual assessment21. This may overcome some of the difficulties that arise from a 226 
inhomogeneous background tissue used for comparison that may lead to interobserver 227 
disagreement in visual analysis.  The study by Murphy et al. demonstrated good inter-228 
observer agreement using a similar method of visual assessment with confirmatory semi-229 
quantitative assessment of reference background FDG uptake in the liver and blood pool. Our 230 
study shows similar results using a visual assessment of SPN FDG uptake and reference 231 
background tissue uptake, and importantly, this was observed in reporters with varying levels 232 
of experience in PET-CT reporting and across different institutions, suggesting that the BTS 233 
scale is reproducible and not due to common training in one centre alone. 234 
235 
The 3-point visual scale had the lowest inter-observer concordance. This could be explained 236 
by a small proportion of cases being classified on opposite ends of the 3-point scale (i.e. one 237 
reporter scored a SPN a   a d he he  a   he ea  he  e e categorized into 238 
adjacent categories for the 4- i  cale c ed     l   categories apart in the 239 
5- i  cale a c e f    Thi  disagreement could not be attributed to lack of240 
reporter experience as, even when novice reporters were excluded from analysis, 5 cases 241 
(10%) were categorised in this manner. Hence reliability was likely lower for the 3-point scale 242 
because of these cases being classified at opposite ends of the scale. It should also be noted 243 
that the reduced agreement of the 3-point scale could reflect the small sample size in our 244 
study, and that over a larger population, a difference might not have been observed. 245 
Nevertheless, the simplified 3-point scale did not perform better than the standard BTS scale 246 
recommended in the 2015 BTS guidelines. 247 
12
248 
Overall accuracy of FDG PET-CT to discriminate malignant and benign SPNs, as measured by 249 
ROC analysis, did not vary with the visual assessment scale used, and although semi-250 
quantitative assessment of FDG uptake performed equally to visual assessment, it did not 251 
improve diagnostic accuracy to a statistically significant degree. This concurs with previous 252 
data reporting that use of semi-quantitative measurement does not improve the sensitivity 253 
of PET-CT22, but can improve its specificity23,24. Although they may not have played a 254 
significant role in our study, in general there are several factors that can limit the use of a 255 
semi-quantitative measure for distinguishing malignant and benign SPNs. First, technical 256 
factors can limit the standardisation of SUV values across different scanner and sites where 257 
scan technique, for example reconstruction algorithms, may vary and therefore so too will 258 
the SUV measurements25. All the images used in this study were acquired in a single 259 
institution. Using an alternative reconstruction algorithm has recently been shown to increase 260 
the Herder score for SPNs, although not the overall diagnostic performance of the Herder 261 
scale, for example 12. Second, studies utilising semi-quantitative measures typically use a 262 
single cut-off value to distinguish benign and malignant nodules26, and typically do not 263 
include a validation cohort to test their cut-off values9,27, whereas the use of visual ordinal 264 
scales can reflect increasing likelihood that a nodule is malignant and overcome the 265 
difficulties of semiquantitative measurement8. Lastly, the calculated SUV can be erroneous 266 
due to tracer extravasation or inaccurate patient weight. 267 
268 
The diagnostic accuracy of both visual assessment scales and semi-quantitative 269 
measurements were lower in this study than previously reported by others2,9,28. This may 270 
be explained by the high proportion of malignant SPNs included in this patient cohort, which 271 
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might have influenced test sensitivity and specificity29. Our results are similar to those of 272 
Lopez et al. who also had a high prevalence of malignant nodules in their study sample23 and 273 
to Murphy et al. whose prevalence of malignancy was 77%12. The high proportion of current 274 
or former smokers in our patient cohort is also likely to have influenced the AUC, as it is known 275 
that in higher risk patients, FDG PET-CT has reduced specificity9. Finally, the mean SUVmax for 276 
benign SPNs in the study was 2.5, which in other studies27,30 is taken as the threshold for 277 
assigning a nodule as malignant on PET-CT, suggesting that our sample may have over-278 
represented benign SPNs (i.e. inflammatory or infective SPNs) with fal e  i i e FDG 279 
uptake31 compared with other studies. This will have further reduced the specificity of 280 
assessment. The accuracy of visual assessment might have been improved by using semi-281 
quantitative assessment of uptake in reference tissues to confirm the results of visual 282 
assessment, as used in Deauville criteria21 and by Murphy et al12. 283 
284 
The study had a number of important limitations. First, 50 patients is a relatively small sample 285 
size, and it is possible that a larger cohort may have revealed differences in accuracy and/or 286 
reliability between the BTS and 5-point scales. Second, not all diagnoses were confirmed 287 
histologically, and therefore it is possible that this introduced inaccuracy in the classification 288 
of a SPN being definitely malignant or benign, again which would affect the overall diagnostic 289 
accuracy. However, each scale would be similarly affected, and this should not limit the 290 
comparison between them. Furthermore, these criteria reflect the reality of clinical practice, 291 
when treatment decisions are not always based on histological diagnosis. The images used in 292 
assessment were acquired on different scanners, using different imaging conditions which 293 
introduces a potential source of variation in the image quality, however this should not have 294 
a strong effect on the comparative assessment of different assessment methods. Lastly, this 295 
14
was a retrospective analysis on non-consecutive patients which is potentially a source of bias, 296 




Our study confirms recent single-centre experiences and extends this to demonstrate that 301 
the BTS scale can be applied consistently in the assessment of SPNs by observers working at 302 
different centres and by individuals with limited prior PET-CT interpretation experience. The 303 
BTS scale is ad ca ed i  a i al g ida ce f  e al a i  f SPN  a d al h gh i  ld be 304 
expected that the scale is easily reproducible across multiple institutions, our study confirms 305 
that this is the case. The BTS scale, which is being increasingly used as part of risk stratification 306 
of SPNs has an accuracy which is not surpassed by alternative visual or semi-quantitative 307 
assessment scales. 308 
309 
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Caption for Figure 1: 434 
435 
Maximum intensity projection (MIP) image from 5 patients with SPN that demonstrate 436 
increasing FDG uptake (from right to left), and illustrate examples of each category using the 437 
5-point visual assessment scale. From the right-hand image, an example of no uptake,438 
through to the left-hand image showing uptake above that of the liver. Black circles indicate 439 
the location of the SPN being assessed. MBP = mediastinal blood pool. 440 
441 
Figure 2  Receiver operator curves for visual assessment scales and semiquantitative 442 
assessment 443 
444 
Caption for Figure 2: 445 
20
4 receiver-operator curves demonstrating similar diagnostic performance For visual uptake 446 
scales and semiquantitative assessment compared to the BTS scale. 447 
 448 
Table 1 - Reconstruction parameters for each scanner 449 














BLOB-OS-TF SS-Simul DLYD 144 or 169 4.0 x 4.0 x 4.0 
450 
Key: 451 
OSEM  Ordered subsets expectation maximisation 452 
BLOB-OS-TF  Spherically symmetric basis function ordered subset algorithm 453 
DLYD  delayed event subtraction 454 
 455 




Uptake 3-point scale BTS scale 5-point scale
Indiscernible from background lung 
1 
1 1 
Greater than lung but less MBP 
2 
2 
Equal to MBP 2 3 
Greater than MBP but less than liver 
3 
3 4 
Greater than liver 4 5 
MBP  mediastinal blood pool 
21
Table 3  Demographic data and nodule characteristics (n=50) 460 
461 
Demographic Value 
Median age, years (IQR) 67 (62-75) 
Male gender (%) 21 (42%) 
Smoking status (%) 
Current or former smoker  40 (80%) 
Never smoked 7 (14%) 
Smoking status undocumented 3 (6%) 
Diagnosis (%) 
Primary lung cancer 30 (60%) 
Metastases from extra-pulmonary 
primary malignancy 
7 (14%) 
 Colorectal adenocarcinoma 5 (10%) 
 Cervical squamous cell carcinoma 1 (2%) 
    Pancreatic large cell carcinoma 1 (2%) 
Benign nodule 13 (26%) 
Median nodule diameter, mm (IQR) 16 (11.5  23.5) 
IQR = interquartile range 
462 
463 
Table 4  Inter-observer agreement for visual assessment scales 464 
 465 
Visual assessment scale 
Agreement: All observers 
ICC (95% CI) 
Agreement: Expert observers 
ICC (95% CI) 
3-point scale 0.70 (0.59 - 0.80) 0.64 (0.49 - 0.76) 
BTS scale 0.78 (0.69 - 0.85) 0.77 (0.67 - 0.85) 
5-point scale 0.78 (0.68 - 0.86) 0.75 (0.63 - 0.84) 





Table 5  - Accuracy of visual assessment scales and semiquantitative assessment 469 
470 
Assessment method Area under ROC 
p value* 
(versus 4-point BTS scale) 
3-point scale 0.715 0.08 
BTS scale 0.768 NA 
5-point scale 0.768 NA 
SUVmax 0.794 0.43 
* t-test  as outlined by Hillis et al.








 British Thoracic Society scale of FDG uptake has good inter-observer agreement. 
 British Thoracic Society scale is as reliable as 3 and 5 point visual scales. 
 Visual assessment showed good agreement between reporters across institutions. 
 Semi-quantitative assessment did not improve the diagnostic accuracy. 
High igh
